Health
Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD
Headline as filed by Times of India World.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Times of India World | Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD |
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was admin |
0m | timesofindia.indiatimes.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.